Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone.

Huang TH, Wei SH, Kuo HI, Hou HY, Kuo CW, Tseng YL, Lin SH, Wu CL

Open source

DOI
10.3390/biomedicines12020402
Published
2024 Feb 8
Container
Biomedicines
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/biomedicines12020402,
  title = {Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone.},
  author = {Huang TH and Wei SH and Kuo HI and Hou HY and Kuo CW and Tseng YL and Lin SH and Wu CL},
  year = {2024},
  journal = {Biomedicines},
  doi = {10.3390/biomedicines12020402},
  url = {https://doi.org/10.3390/biomedicines12020402}
}

RIS

TY  - JOUR
TI  - Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone.
AU  - Huang TH
AU  - Wei SH
AU  - Kuo HI
AU  - Hou HY
AU  - Kuo CW
AU  - Tseng YL
AU  - Lin SH
AU  - Wu CL
PY  - 2024
JO  - Biomedicines
DO  - 10.3390/biomedicines12020402
UR  - https://doi.org/10.3390/biomedicines12020402
ER  - 

APA

TH, H., SH, W., HI, K., HY, H., CW, K., YL, T., SH, L., & CL, W. (2024). Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone.. Biomedicines. https://doi.org/10.3390/biomedicines12020402

Source records